Idexx Laboratories IDXX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 247.1%+3.7pp | 246.3%+4.0pp | 245.6%+4.5pp | 244.6%+4.3pp | 243.4%+3.6pp | |
| Operating margin | 125.7%+10.0pp | 123.2%+6.7pp | 120.5%+3.1pp | 118.1%-0.5pp | 115.6%-4.2pp | |
| Net margin | 98.3%+7.9pp | 96.4%+5.5pp | 94.6%+3.4pp | 92.5%+0.9pp | 90.4%-1.4pp | |
| EBITDA margin | 139.1%+10.3pp | 136.7%+7.4pp | 134%+3.8pp | 131.5%+0.3pp | 128.9%-3.6pp | |
| Free cash flow margin | 91.5%+6.4pp | 88.7%+3.8pp | 84.8%-0.4pp | 82.3%-1.3pp | 85.1%+6.8pp | |
| Returns | ||||||
| Return on equity | 268.6%+29.0pp | 255%+2.8pp | 246.5%-28.8pp | 241.3%-67.4pp | 239.7%-108pp | |
| Return on assets | 124.8%+16.6pp | 118.9%+9.8pp | 114.1%+4.0pp | 110.5%-1.4pp | 108.2%-5.7pp | |
| Return on invested capital | 213.5%+31.8pp | 202%+16.6pp | 194.7%+1.6pp | 187.9%-15.4pp | 181.7%-30.5pp | |
| Efficiency | ||||||
| Asset turnover | 5.1×+0.3× | 4.9×+0.1× | 4.8×0.0× | 4.8×-0.1× | 4.8×-0.2× | |
| Inventory turnover | 16.8×+1.2× | 16.3×+0.8× | 16×+0.5× | 15.7×+0.3× | 15.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.6×-0.6× | 4.7×-1.0× | 4.8×-1.2× | 5×-0.9× | 5.3×-0.6× | |
| Quick ratio | 3.4×-0.4× | 3.4×-0.8× | 3.4×-1.0× | 3.6×-0.8× | 3.8×-0.4× | |
| Cash ratio | 0.6×-0.5× | 0.6×-0.7× | 0.7×-0.8× | 0.9×-0.7× | 1.1×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.6×-0.4× | 1.7×-0.2× | 1.8×-0.2× | 1.9×-0.4× | 2×-0.6× | |
| Debt-to-assets | 0.7×-0.2× | 0.8×-0.1× | 0.8×-0.1× | 0.9×-0.1× | 0.9×-0.2× | |
| Net debt / EBITDA | 1.2×-0.3× | 1.4×0.0× | 1.5×+0.1× | 1.5×+0.1× | 1.5×-0.3× | |
| Interest coverage | 143×+4.2× | 143.9×+11.4× | 145.1×+22.3× | 143.6×+31.1× | 138.8×+36.5× | |
| Per Share | ||||||
| Book value per share | $76.59+1.8% | $74.85-1.9% | $74.20-0.8% | $74.33+5.0% | $75.27+16.1% | |
| Valuation | ||||||
| Market capitalization | $192.43B+28.2% | $181.83B+13.0% | $161.66B-6.7% | $152.3B-9.2% | $150.12B-11.2% | |
| Enterprise value | $194.14B+27.7% | $183.75B+13.0% | $163.63B-6.4% | $154.25B-9.0% | $152B-11.2% | |
| Price / earnings | 184.8×+12.5× | 182.1×-3.9× | 169.2×-33.2× | 167.6×-30.8× | 172.2×-31.0× | |
| Price / sales | 45.4×+6.5× | 44×+1.8× | 40.2×-6.0× | 38.8×-6.7× | 38.9×-7.7× | |
| Price / book | 124.3×+28.2× | 119.1×+17.9× | 106.7×-4.4× | 99.8×-13.5× | 96.1×-29.7× | |
| EV / EBITDA | 131.7×+9.4× | 129.8×-2.2× | 120.9×-22.2× | 119.4×-20.7× | 122.3×-20.3× | |
| EV / sales | 45.8×+6.4× | 44.5×+1.8× | 40.7×-6.0× | 39.3×-6.7× | 39.4×-7.8× | |
| Free cash flow yield | 8.1%-0.7pp | 8.2%0.0pp | 8.6%+1.2pp | 8.6%+1.2pp | 8.8%+2.1pp | |
| Earnings yield | 8.7%-0.7pp | 8.9%+0.2pp | 9.6%+1.6pp | 9.6%+1.5pp | 9.4%+1.5pp | |
| PEG ratio | 9.7×-25.5× | 19.5×-6.3× | 24.4×+3.9× | 30.9×+17.5× | 35.2×+26.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Idexx Laboratories's profit margins?
- Idexx Laboratories (IDXX) runs a 62.1% gross margin and a 31.6% operating margin, with a 24.6% net margin.
- Where do Idexx Laboratories's ratios come from?
- Every ratio is computed from Idexx Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
